{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:37:53Z","timestamp":1772087873751,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and safety of toripalimab combined with albumin-bound paclitaxel and cisplatin\/carboplatin as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R\/MHNSCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-five patients with advanced R\/MHNSCC admitted to Hunan Cancer Hospital (January 2021-December 2023) received first-line treatment with toripalimab plus albumin-bound paclitaxel and cisplatin\/carboplatin. Efficacy was assessed using RECIST 1.1, and adverse events were evaluated according to NCI-CTCAE 5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 35 patients were assessed for efficacy, with partial response (PR) in 21 (60.0%), stable disease (SD) in 6 (17.1%), and progressive disease (PD) in 8 (22.9%). The overall response rate (ORR) was 60.0%, and the disease control rate (DCR) was 77.1%. The follow-up period concluded on August 10, 2024, with a median follow-up duration of 22.0 months (range: 15.0-27.0 months). Among the cohort, 8 patients experienced PD, and 7 patients succumbed to the disease; 13 patients continued treatment without disease progression. The median progression-free survival (PFS) for the entire cohort was 7.0 months (95% CI: 4.4-9.6 months), while the median overall survival (OS) had not yet been reached. Further results of Cox proportional hazards regression analysis showed that programmed death-ligand 1 (PD-L1) expression status was an independent risk factor for progression-free survival (PFS), whereas bone metastasis status and a history of surgery for head and neck squamous cell carcinoma were key risk factors for overall survival. The primary adverse reactions observed included bone marrow suppression, hypothyroidism, rash, neurotoxicity, pneumonia, and abnormal liver function. The majority of patients experienced grade I to II adverse reactions; however, one patient (4.3%) exhibited grade III adverse reactions, specifically an immune-related rash, and two patients experienced grade IV adverse reactions, one with leukopenia and the other with neutropenia. Notably, there were no deaths attributable to toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Toripalimab combined with albumin-bound paclitaxel and cisplatin\/carboplatin demonstrates promising efficacy with manageable adverse reactions as first-line treatment for R\/MHNSCC. However, further research involving expanded sample sizes and randomized controlled trials is warranted to substantiate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1674467","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:05Z","timestamp":1772083745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of nanoparticle albumin-bound paclitaxel combined with toripalimab and platinum as first-line treatment for Chinese patients with recurrent or metastatic head and neck cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinlan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Urology the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","volume-title":"Cancer Facts & Figures\u00a02019","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7518\/hxkq.2022.06.001","article-title":"Expert consensus on immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma","volume":"40","author":"Liu","year":"2022","journal-title":"West China J Stomatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105173","DOI":"10.1016\/j.oraloncology.2020.105173","article-title":"Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopha r ynx: EH NS-ESMO -ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.3390\/ijms23147889","article-title":"Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma","volume":"23","author":"Ghosh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.19401\/j.cnki.1007-3639.2024.04.010","article-title":"Expert consensus on the treatment of recurrent\/metastatic head and neck squamous cell carcinoma with immune checkpoint inhibitors (2024 edition)","volume":"34","author":"Ye","year":"2024","journal-title":"Chin J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/1759-7714.13356","article-title":"Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac Cancer"},{"key":"B11","article-title":"Clinical observation of albumin-bound paclitaxel combined with nedaplatin in the treatment of advanced head and neck squamous cell carcinoma","volume":"30","author":"Lijun","year":"2021","journal-title":"China Pharm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01721","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","volume":"18","author":"Qiao","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/cancers12113427","article-title":"Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: A retrospective multicenter study of 88 patients","volume":"12","author":"Matsuki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2591","article-title":"Induction chemotherapy followed by cetuximab radiotherapyis not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007\u201302 phase III randomized trial","volume":"36","author":"Geoffrois","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: mechanisms and therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3390\/ijms19061709","article-title":"Cellular and molecular mediators of bone metastatic lesions","volume":"19","author":"Battafarano","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.3390\/cancers14235727","article-title":"Bone metastasis of breast cancer: molecular mechanisms and therapeutic strategies","volume":"14","author":"Pang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2016.1209689","article-title":"Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients","volume":"50","author":"Klaff","year":"2016","journal-title":"Scand J Urol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3251051","DOI":"10.1155\/2022\/3251051","article-title":"Analysis of related risk factors and prognostic factors of gastric cancer with bone metastasis: A SEER-based study","volume":"2022","author":"Xiaobin","year":"2022","journal-title":"J Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e069908","DOI":"10.1136\/bmjopen-2022-069908","article-title":"Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study","volume":"13","author":"Zhang","year":"2023","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/curroncol32010042","article-title":"Impact of bone-modifying agents on post-bone metastasis survival across cancer types","volume":"32","author":"Tamiya","year":"2025","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"20","author":"Chera","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667650","article-title":"The risk of immune-related thyroid dysfunction induced by PD-1\/PD-L1 inhibitors in cancer patients: an updated systematic review and meta-analysis","volume":"12","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1039\/d4cc90283a","article-title":"Co-delivery of all-trans-retinoicacid enhances the anti-meta stasis effect of albumin-bound paclitaxel nano particles","volume":"53","author":"Huang","year":"2016","journal-title":"Chem Commun(Camb)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12032-022-01754-4","article-title":"Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial","volume":"39","author":"Kanbayashi","year":"2022","journal-title":"Med Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9430952","DOI":"10.1155\/2022\/9430952","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy caused by nanoparticle albumin-bound paclitaxel in advanced breast cancer","volume":"2022","author":"Guo","year":"2022","journal-title":"BioMed Res Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13058-020-01319-1","article-title":"EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer","volume":"21","author":"Biganzoli","year":"2020","journal-title":"Breast Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1674467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:08Z","timestamp":1772083748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1674467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1674467"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1674467","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1674467"}}